Abstract-The antithrombotic effect of a prostaglandin E, derivative, OP-1206 (17S-20-dimethyl-trans-42-PGE,) •cr-cyclodextrin clathrate (OP-1206•a-CD), was compared with that of acetylsalicylic acid (ASA) in a electrically induced thrombosis model of guinea-pig mesenteric arteries using intact animals and animals subjected to the superfusion of tranylcypromine (TC, 15 mM) over their mesentery. The drug-effect was assessed by the change of the threshold voltage for the thrombus formation. 1) TC (1.5-15 mM) lowered the threshold voltage, and the effect was comparable to its inhibitory effect on PGI2 formation in vitro, suggesting that PGI2 generated in mesenteric arteries acts to prevent thrombus formation. 2) In intact animals, OP-1206•a-CD at doses of 0.01-0.3 mg/kg, p.o. (as OP-1206), significantly and dose-dependently elevated the threshold voltage. ASA (30-1000 mg/kg, p.o.) significantly elevated the threshold voltage, but the effect reached to its maximum at 100 mg/kg and lessened with further increase of ASA. 3) In TC-treated animals, OP-1206•a-CD elevated the threshold voltage dose-dependently, but the elevation of threshold voltage by ASA reached to its plateau level which was significantly lower than that obtained with OP-1206•a-CD at 0.3 mg/kg, indicating that the antithrombotic effect of ASA is incomplete in this model. 4) Threshold voltages in TC-treated animals given OP-1206•a-CD was significantly lower than those in intact animals at all doses tested, but threshold voltages in TC-treated and intact animals given ASA at 300-1000 mg/kg were not different, suggesting that high doses of ASA inhibits PGI2 formation in vivo. Thus, the antithrombotic effect of ASA was restricted by its inhibitory effect on PGI2 formation and its incomplete inhibition on thrombus formation, while such differ ences were not observed in OP-1206•a-CD.
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Platelets play a important role in the initiation of arterial thrombosis.
Therefore, a variety of compounds inhibiting platelet functions were studied with regards to their antithrombotic potential (1) . Among these, acetylsalicylic acid (ASA) has been studied for many years, and it has also been used for the treatment of thrombotic diseases such as transient ischemic attack in man (2).
However, the antithrombotic effect of ASA is thought to be restricted by its inhibitory effect on vascular synthesis of prostaglandin 12 (PGI2) (3) . PGI2 is the most potent endogenous inhibitor of platelet functions (4) and may play an important role in the prevention of thrombus formation (5) .
A prostaglandin E, derivative, OP-1206, 17S-20-dimethyl-trans-42-PGE1, also po tently inhibits platelet functions in vitro (6) . Its oral administration also inhibits platelet aggregation and adhesiveness, and it prevents thrombocytopenia induced by the injection of ADP and collagen (7) . However, effects of OP-1206 on thrombus formation and PGI2 formation have not been known.
Materials and Methods
Animals: Male guinea-pigs of the Hartley strain, weighing 360-660 g, were used. A commercial diet (RC-4, Oriental Yeast Co., Japan) and water were given ad libitum.
Experimentally induced thrombosis: Guinea-pigs anesthetised with pentobarbital sodium (75 mg/kg, s.c.) were subjected to abdominal incision. The jejunum part of the intestinal loops was extended over a plastic plate, and the mesentery was superfused with saline (37°C). A platinum electrode (200 um in diameter with shapened tip) as an anode was touched to the mesenteric artery (30 60 /im in diameter), and a cathodal electrode was fixed to the edge of the incision. Then, the mesenteric artery was electrically stimu lated with a single rectangular pulse (pulse duration of 1000 msec). The voltage of the stimulation was changed in a stepwise manner at 2.5 V intervals (5.0-30 V). The thrombus formation was microscopically observed for 10 min after each stimulation, and the lowest voltage causing complete occlusion of the vessel by thrombi (threshold voltage for thrombus formation) was determined. Drug-effect was assessed by the change of the threshold voltage.
PGI2 formation in aortic tissue in vitro: The formation of PGI2 in guinea-pig aorta was estimated by a bioassay based on the inhibitory effect of PGI2 on platelet ag gregation as previously described (9). Rings of aorta (10 mg) were incubated with 400 ,ul of saline buffered with Tris (TBS, pH 7.6) for 5 min at 22°C under the presence or absence of test compounds. Then, an aliquot of the medium was added to platelet-rich plasma preincubated for 1 min at 37'C, and platelet aggregation was induced by ADP (1-2x10-6 M). 
Results
Effects of tranylcypromine on aortic PGI2 formation in vitro and thrombus formation in mesenteric arteries: Tranylcypromine (TC) at 0.75-7.5 mM inhibited the aortic PGI2 formation in vitro in a concentration dependent manner (Fig. 1A) . TC (1.5-15 mM) superfused over the mesentery also lowered the threshold voltage for the thrombus formation (Fig. 1 B) (Fig. 2) . The threshold voltages in TC-treated animals given OP 1206•a-CD were significantly and con sistently lower than those in intact animals given OP-1206•a-CD at all doses tested. ASA (30-1000 mg/kg, p.o.) also elevated threshold voltages in intact and TC-treated animals significantly, although its effect was 1/3000 times less potent than that of OP 1206•a-CD (Fig. 3) .
However, the antithrombotic property of ASA was somewhat different from that of OP-1 206-a-CD.
In intact animals, the elevation of threshold voltage by ASA reached to its maximum of 21 V at 100 mg/kg, and a further increase of ASA caused the reduction of its antithrombotic effect (Fig.  3) . In TC-treated animals, the elevation of threshold voltages reached to its plateau of 17 V at 100-1000 mg/kg. The threshold voltage of this plateau level was signifi cantly lower than that obtained with OP 1206•a-CD at 0.3 mg/kg in TC-treated animals.
The threshold voltages of TC treated animals given ASA at 10-100 mg/kg were significantly lower than those in intact animals given the same doses of ASA, but threshold voltages of intact and TC-treated animals given ASA at 300-1000 mg/kg were not different (Fig. 3) .
In vitro effect of OP-1206•a-CD and ASA on PGI2 formation in aorta: ASA at 300 ,ag/ml inhibited PGI2 formation in guinea-pig aortic tissue, but OP-1206•a-CD at 0.5-1.0 ng/ml did not (Table 1) . Fig. 3 . Antithrombotic effect of acetylsalicylic acid in electrically induced thrombosis model in intact (0) and tranylcypromine-treated (0) guinea-pigs. Acetylsalicylic acid was orally given 3 hr before the electrical stimulation. Other legends to the figure are the same as described in Fig. 2 . reported by us (7, 10), indicating that the antithrombotic effect of these compounds originated from their inhibitory activities on platelet function. However, the dose-effect relationships of these two compounds were somewhat different.
Firstly, in TC-treated animals, the anti thrombotic effect of OP-1206•a-CD increased in a dose-dependent manner, whereas that of ASA reached to its plateau level which was significantly lower than the threshold voltage obtained with OP-1206•a-CD at 0.3 mg/kg. The difference may come from the different inhibitory mechanism of OP 1206•a-CD and ASA on platelet functions. A compound that increases platelet cyclic AMP like OP-1206 (6) inhibits all of the activation process of platelets (11), but ASA only inhibits an activation process related to arachidonate-thromboxane pathway (12).
Secondly, the consistent differences between threshold voltages in intact and TC-treated animals given OP-1206•a-CD indicate that the compound has little effect on PGI2 formation. On the contrary, threshold voltages in intact and TC-treated animals given ASA at 300-1000 mg/kg were not different. Thus, ASA at high doses may inhibit PGI2 formation as well as thrombus formation, and this inhibition of PGI2 formation may explain a part of the lessened antithrombotic effect of ASA at these doses in intact animals. A similar lessened antithrombotic effect or prothrombotic effect of ASA has been reported earlier (3, 13).
The above results are coincident with the result of in vitro experiments on PGI2 formation in aortic tissue. OP-1206•a-CD (0.5-1.0 ng/ml) did not inhibit PGI2 formation, although these concentrations of OP-1206 markedly inhibited guinea-pig platelet functions (6) . ASA inhibited PGI2 formation at 300 /tg/ml. This concentration is 30-100 times higher than the concen trations of ASA inhibiting platelet adhesi veness (10), and the ratio is roughly com parable to the ratio of the prothrombotic dose/antithrombotic dose of ASA (ratio: 10-30). The discrepancy may come from the difference of the vascular tissue used, i.e., aorta and mesenteric artery.
In summary, ASA inhibited thrombus formation, but its antithrombotic effect was lessened at its high doses. The reduction of the antithrombotic effect may result from its inhibitory effect on PGI2 formation and its incomplete inhibition of the activation process of platelets. In contrast to ASA, OP 1206•a-CD inhibited thrombus formation in a dose-dependent manner. This property of OP-1206•a-CD together with its vasodilating effect (7) may be favorable for the treatment of ischemic vascular diseases.
